The news directly mentions Emergent BioSolutions (NYSE:EBS) and the Buy rating reiterated by Benchmark analyst Robert Wasserman. This positive rating and maintained price target of $22 indicate a potential upside for the stock in the short term, which is likely to have a positive impact on its price.